Business
Fagron delivers strong performance with 11% topline growth and 12% increase in REBITDA for H1 2025
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 31 July 2025 – 7:00 AM CET Fagron delivers strong performance with 11% topline growth and 12% increase in REBITDA for H1 2025 Fagron, the leading global player in pharmaceutical compounding today publishes its first half results for the period ending 30 June 2025. Key Highlights Strong revenue performance with 10.9% reported revenue growth (14.4% at CER1) and 11.3% organic growth at CER 12.3% REBITDA increa
About this update from Fagron Sa
Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 31 July 2025 – 7:00 AM CET Fagron delivers strong performance with 11% topline growth and 12% increase in REBITDA for H1 2025 Fagron, the leading global player in pharmaceutical compounding today publishes its first half results for the period ending 30 June 2025. Key Highlights Rafael Padilla, CEO of Fagron : “ I am proud of our strong first half performance, with all regions contributing to profitable growth. We have made meaningful operational progress, notably in product availability and procurement savings which have translated into top-line and margin expansion. EMEA delivered another solid performance, reflecting the strength of our geographical diversification and recent M&A integration. In Latin America , we saw standout growth in our Brands business in Brazil, supported by a robust innovation pipeline. North America remains our growth engine, as we onboard new customers, broaden our product portfolio, and execute against our operational excellence agenda. To maintain our strong growth momentum in the mid-term, we are making a one-off investment to expand Anazao’s 503B facility in Las Vegas. This will significantly increase our capacity, enabling us to meet the rising demand and further scale our lifestyle and prevention offering in North America. We are also pleased to announce four strategic acquisitions that reinforce our commitment to disciplined, value-accretive M&A. These acquisitions expand our presence into Australia and Serbia and strengthen our market position in the UK and are fully aligned with our long-term ambitions and investment approach . We also wish to thank Els Vandecandelaere , who will be stepping down from the Board. Her guidance and commitment have been instrumental in Fagron’s development into a leader in personalized medicine. Looking ahead, we remain confident in our outlook and are reiterating both our FY 2025 and mid-term guidance. With a resilient, flexible business model and clear strategic focus, we are well positioned to continue to deliver sustainable growth. ” 1 Constant Exchange Rate Attachment